Tyra Biosciences (TYRA) EBT (2020 - 2026)

Tyra Biosciences (TYRA) has 7 years of EBT data on file, last reported at -$363.7 million in Q1 2026.

• Quarterly EBT fell 774.12% year-over-year to -$363.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$515.6 million (down 89.85% YoY) and the FY2025 annual result came in at -$306.6 million, down 154.92% from the prior year.
• EBT eased to -$363.7 million in Q1 2026, from -$34.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$12.7 million in Q4 2022 to a low of -$363.7 million in Q1 2026.
• A 5-year average of -$69.3 million and a median of -$41.9 million in 2025 frame the typical range for EBT.
• Annual changes were most pronounced in 2025 — EBT soared 44.54% — and 2026, when it plunged 774.12%.
• Tracing TYRA's EBT over 5 years: stood at -$12.7 million in 2022, then slumped by 79.59% to -$22.8 million in 2023, then declined by 13.32% to -$25.9 million in 2024, then tumbled by 31.55% to -$34.0 million in 2025, then slumped by 968.75% to -$363.7 million in 2026.
• The last three EBT figures came in at -$363.7 million (Q1 2026), -$34.0 million (Q4 2025), and -$75.9 million (Q3 2025), per Business Quant data.